VRAX logo

VIRAX BIOLABS GROUP LTD

VRAXNASDAQ
πŸ† #5208 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track VRAX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2M
Small Cap
πŸ“ˆRevenue Growth (YoY)
96.4%
High Growth
πŸ“ŠGross Margin
62.0%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
38.9x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for VRAX.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.29 – $21.75
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
1.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$12,423
Last Q Revenue
$12,423
P/E Ratio
β€”
P/S Ratio
38.9x
EPS (TTM)
$-23.09
Dividend Yield
β€”
Dilution (1yr)
+108.7%
VRAX logo

VIRAX BIOLABS GROUP LTD

VRAX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12Kβ–² +96.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.9%β–Ό βˆ’107.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$6Mβ–² +3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’5.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
398Kβ–² +108.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About VIRAX BIOLABS GROUP LTD

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.